诺和诺德再下一城！减重版司美格鲁肽在中国斩获心血管适应症

Core Insights - Novo Nordisk's semaglutide injection (brand name: Ozempic) has received approval from the National Medical Products Administration (NMPA) in China for cardiovascular indications, aimed at reducing the risk of major cardiovascular adverse events in adults with cardiovascular disease and a BMI ≥ 27 kg/m² [1][2] Group 1: Product Approval and Efficacy - The approval is based on the SELECT trial, which is the largest cardiovascular outcomes trial completed for patients with obesity and cardiovascular disease, involving 17,604 participants [4] - The SELECT trial results indicated that semaglutide injection reduced the risk of major adverse cardiovascular events (MACE) by 20%, cardiovascular death by 15%, heart failure composite endpoint by 18%, and all-cause mortality by 19% compared to placebo [4] - Early treatment with semaglutide showed protective effects on the heart before significant weight loss occurred, suggesting benefits in reducing MACE risk regardless of weight reduction [4] Group 2: Market Context and Health Implications - Approximately 4 million people die from cardiovascular diseases in China each year, accounting for over 40% of total deaths, with obesity being a significant independent risk factor for cardiovascular morbidity and mortality [3] - The treatment guidelines in both Europe and China emphasize the importance of weight management in overweight/obese patients to lower cardiovascular risks, with semaglutide being the only drug recommended for this purpose [3][4] - Real-world studies, such as the STEER study, demonstrated that patients treated with semaglutide had a 57% lower risk of heart attack, stroke, and all-cause mortality compared to those treated with tirzepatide, reinforcing the unique cardiovascular benefits of semaglutide [5] Group 3: Company Strategy and Future Outlook - Novo Nordisk aims to transform obesity treatment concepts and improve cardiovascular outcomes for overweight and obese patients through the broader clinical application of semaglutide [5] - The company is committed to addressing diverse needs in obesity treatment and continues to innovate in its research pipeline to combat obesity stigma and promote effective prevention strategies [5]